BIVI Stock — Biovie Inc

Biovie Inc (BIVI)

Updated October 16, 2026.

BIVI is a Stock. Its deepest 1-year drawdown was 57.5%.

BioVie Inc. is a clinical-stage biopharmaceutical company developing drug therapies for neurological and neurodegenerative disorders and advanced liver disease, with lead programs including BIV201 for liver cirrhosis complications in Phase 3 trials and Bezisterim for Alzheimer's disease and Parkinson's disease, also in late-stage development. The company does not currently distribute to shareholders. BioVie appeals to investors seeking exposure to early-stage biotech development rather than current income.

BIVI performance

Returns are updating. BIVI's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 57.5%.

BIVI key facts

Asset type

Stock

Asset class

Equity

Inception date

05/05/2014

Distribution frequency

None

Last close

$1.20 (as of 2026-10-16)

Market cap

$10,419,252

Average volume

275329.0

Payment date

11/22/2019

Beta

0.731

Payout ratio

0.0%

EPS

$-3.05

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

BIVI risks and drawbacks

The deepest 1-year drawdown on record here is 57.5%.

Who may consider BIVI — and who may not

It is a weaker fit for investors who need monthly cash flow (BIVI does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on BIVI

• All tickers starting with B

Tagged: Healthcare.

Frequently asked questions